A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated with Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

Trial Identifier: 3475A-F65
Sponsor: MSD
Start Date: October 2024
Primary Completion Date: November 2028
Study Completion Date: November 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary - English

Trial Locations

Country Location
Chile, Coquimbo La Serena., Coquimbo, Chile, 1720430
Chile, Region M. de Santiago Santiago, Region M. de Santiago, Chile, 7580206
New Zealand, Auckland Auckland, New Zealand, 1023
Poland, Malopolskie Krakow, Malopolskie, Poland, 30-727
Poland, Mazowieckie Warszawa, Mazowieckie, Poland, 02-781
Spain, Castilla y Leon Salamanca, Castilla y Leon, Spain, 37007
Spain, Madrid Madrid, Spain, 28041
United States, NY Westbury, NY, United States, 11590